The bioinformatics industry in DACH encompasses innovative companies focused on integrating biology with data analysis techniques. Firms in this sector are engaged in genomics, drug discovery, and personalized medicine, leveraging massive datasets to enhance healthcare outcomes. With technological advancements like AI and machine learning, bioinformatics plays a crucial role in tackling diseases and streamlining drug development processes. As the demand for precision medicine increases, the industry is poised for impressive growth, with collaborations expanding among pharmaceutical companies, research institutions, and startups improving patient care and therapeutic options across various health challenges.


This list showcases 18 investors active in the DACH bioinformatics sector. The investors include venture capital firms and corporate partners, primarily based in Switzerland and Germany. Most were founded in the late 1990s to early 2000s, showing strong longevity in the market. Each investor varies in size, from smaller firms with a dozen employees to major corporations employing thousands. In 2024, these investors executed numerous deals, focusing on fostering innovation in biotechnology, particularly within bioinformatics.


Top 18 Bioinformatics Investors in DACH


1. Novartis Venture Fund

  • Website: nvfund.com
  • Type: Venture Capital
  • Headquarters: Basel, Basel, Switzerland
  • Founded year: 1996
  • Headcount: 11-50
  • Number of deals in 2024: 10

Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, founded in 1996. The firm specializes in life sciences investments, focusing on providing funding and support to innovative biotechnology and biopharmaceutical companies. Their mission is to help these companies develop novel therapeutics and address unmet patient needs. Notably, the Novartis Venture Fund has been involved in significant transactions within the bioinformatics space, such as their investments in Bionano Genomics, where they participated in multiple funding rounds, including a $53 million Series C financing in 2014 and subsequent Series D rounds in 2016. These investments highlight their commitment to advancing technologies that are crucial for genomic analysis and bioinformatics, making them a key player in this sector.


2. HBM Healthcare Investments AG


HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in the healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in the rapidly evolving healthcare market. Notably, they have participated in significant funding rounds for companies such as Seer, Inc., which raised $55 million to expand its research and development in bioinformatics tools, and Freenome, which secured $300 million for its cancer detection technologies that leverage bioinformatics. Additionally, their early investments in Galileo Genomics highlight their long-standing interest in the bioinformatics space, making them a relevant player in this industry.


3. Nextech Invest


Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer therapeutics. The firm invests in promising drug discovery companies and provides strategic support to help these firms navigate the complexities of drug development. In recent years, Nextech Invest has participated in significant funding rounds for companies that are likely to leverage bioinformatics in their operations. For instance, they were involved in a $120 million private placement for Silence Therapeutics, which focuses on RNA therapeutics, and a $61 million funding round for Hexagon Bio, a company that utilizes computational biology to discover new drugs. Additionally, they participated in a $30 million private placement for Relay Therapeutics, which is advancing its preclinical pipeline with a focus on precision medicine. These transactions highlight Nextech Invest's commitment to supporting innovative biotechnology firms that are at the intersection of drug development and bioinformatics.


4. Novartis

  • Website: novartis.com
  • Type: Corporate
  • Headquarters: Basel, Basel, Switzerland
  • Founded year: 1996
  • Headcount: 10001+
  • Number of deals in 2024: 7
  • LinkedIn: novartis

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company is dedicated to developing and manufacturing innovative medicines aimed at addressing serious diseases across various therapeutic areas. With a workforce of over 10,000 employees, Novartis places a strong emphasis on research and development to enhance patient outcomes. In recent years, Novartis has made significant investments in the bioinformatics space, including participation in funding rounds for companies like Intellia Therapeutics, which focuses on gene editing and delivery systems, and Caribou Biosciences, a pioneer in CRISPR technology. These investments reflect Novartis's strategic interest in advancing biotechnological innovations that are crucial for the future of medicine and healthcare.


5. Leaps by Bayer

  • Website: leaps.bayer.com
  • Type: Venture Capital
  • Headquarters: Berlin, Berlin, Germany
  • Founded year: 2015
  • Headcount: 11-50
  • Number of deals in 2024: 16
  • LinkedIn: leapsbybayer

Leaps by Bayer is a venture capital firm based in Berlin, Germany, founded in 2015. The firm focuses on biotechnology and agriculture, investing in early-stage companies that pursue scientific breakthroughs to tackle major global challenges in health and food security. Leaps by Bayer provides funding and active incubation to support the development of innovative solutions in these sectors. Notably, they have invested in several companies relevant to bioinformatics, such as Gandeeva Therapeutics, which raised $40 million to advance its AI-driven cryo-EM platform for precision medicine. Additionally, they co-led a $100 million Series C financing round for Boundless Bio, which is focused on developing ecDNA-directed therapies. Their recent investment in GRO Biosciences, which raised $60.3 million in Series B funding, further emphasizes their commitment to advancing biotechnology solutions that may include bioinformatics applications.


6. Boehringer Ingelheim Venture Fund

  • Website: boehringer-ingelheim-venture.com
  • Type: Venture Capital
  • Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm founded in 2010, based in Ingelheim Am Rhein, Germany. The fund specializes in investing in pioneering science and biotechnology innovations, particularly within the healthcare sector. They provide both capital and expertise to startups, helping them develop and commercialize their products. Notable transactions include their investment in Sentieon, which raised $3.8 million in Series A funding, and ArrePath, a company that raised $20 million in seed funding to advance its AI and imaging technologies in antibiotic research. Additionally, they have invested in Asgard Therapeutics and etherna immunotherapies, both of which are involved in cutting-edge therapeutic developments, further showcasing their commitment to supporting innovative solutions in the life sciences that often intersect with bioinformatics.


7. Evotec

  • Website: evotec.com
  • Type: Corporate
  • Headquarters: Hamburg, Hamburg, Germany
  • Founded year: 1993
  • Headcount: 5001-10000
  • Number of deals in 2024: 3
  • LinkedIn: evotec

Evotec SE is a biotechnology company based in Hamburg, Germany, founded in 1993. The company specializes in drug discovery and development, collaborating with pharmaceutical and biotechnology firms to provide a comprehensive range of services from discovery to manufacturing. Evotec's strategic acquisitions, such as Aptuit LLC for $300 million, enhance their capabilities in therapeutic areas like respiratory and fibrosis, which often rely on bioinformatics for data analysis and drug design. The acquisition of Just Biotherapeutics for $90 million further strengthens their position in biologics, an area where bioinformatics plays a crucial role in understanding complex biological data. Additionally, their acquisition of Rigenerand Srl for €23 million underscores their commitment to advancing cell therapy, which also intersects with bioinformatics in terms of data management and analysis. Overall, Evotec's focus on innovative solutions and partnerships positions them as a significant player in the bioinformatics landscape.


8. Debiopharm


Debiopharm is a biopharmaceutical company based in Lausanne, Switzerland, founded in 1979. The firm specializes in the development and manufacturing of innovative therapies for cancer and infectious diseases. Debiopharm partners with academic and pharmaceutical institutions to address high unmet medical needs. Notably, they have made significant investments in the bioinformatics space, including a $33 million Series B investment in Nucleai, which develops platforms for immuno-oncology, and a $10 million investment in WhiteLab Genomics, an AI-driven predictive software platform for gene and cell therapies. These transactions highlight Debiopharm's strategic focus on integrating bioinformatics into their investment portfolio, enhancing their capabilities in drug discovery and development.


9. Roche

  • Website: roche.com
  • Type: Corporate
  • Headquarters: Switzerland
  • Founded year: 1896
  • Headcount: 10001+
  • Number of deals in 2024: 5
  • LinkedIn: roche

F. Hoffmann-La Roche AG is a leading healthcare company based in Switzerland, specializing in pharmaceuticals and diagnostics. Founded in 1896, Roche has a long history of developing innovative solutions for various health conditions, particularly in cancer treatments and in-vitro diagnostics. In recent years, Roche has made significant investments in the bioinformatics space, including the acquisition of Foundation Medicine in 2015 for $2.4 billion, which focuses on genomic profiling for cancer treatment. In 2022, Roche invested approximately $350 million in Freenome, a company advancing multiomics technology for cancer detection, further emphasizing their commitment to bioinformatics. Additionally, Roche's acquisition of Mirus Bio in 2008, which specializes in RNA interference delivery platforms, showcases their interest in innovative nucleic acid-based technologies relevant to bioinformatics. These strategic investments highlight Roche's dedication to improving health outcomes through advanced diagnostics and therapeutic solutions.


10. Verve Ventures

  • Website: verve.vc
  • Type: Venture Capital
  • Headquarters: Zurich, Zurich, Switzerland
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 25
  • LinkedIn: investiere-venture-capital

Verve Ventures is a Zurich-based venture capital firm founded in 2010, specializing in deep tech investments across Europe. With a focus on sectors such as climate tech, industrial technology, and health & bio, Verve Ventures provides funding and strategic support to science and technology startups. Notably, they have participated in significant transactions within the bioinformatics context, including OncoDNA, which raised €19 million to enhance its genomic data capabilities, and Scailyte, which raised $658,072 for its systems biology platform. Their involvement in these companies highlights their commitment to advancing health and bio technologies, making them a key player in the bioinformatics investment landscape.


11. BiomedVC

  • Website: biomedvc.com
  • Type: Venture Capital
  • Headquarters: Basel, Basel, Switzerland
  • Founded year: 2003
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: biomedvc

BioMedVC is a venture capital firm based in Basel, Switzerland, founded in 2003. The firm specializes in early-stage investments in the life sciences sector, focusing on supporting biotech startups by providing capital and strategic guidance to help them develop innovative medical solutions. In recent years, BiomedVC has participated in significant funding rounds for companies like TOLREMO therapeutics, which raised multiple Series A rounds to advance their oncology treatments. These investments highlight BiomedVC's commitment to fostering innovation in the life sciences, which often intersects with bioinformatics, particularly in the analysis and interpretation of biological data. Their involvement in the biotech space positions them as a potential investor in bioinformatics-related ventures, making them a relevant player in this field.


12. redalpine


Redalpine is a venture capital firm based in Zurich, Switzerland, founded in 2006. The firm specializes in investing in technology and science sectors, providing funding and strategic support to startups. Redalpine has a strong focus on areas such as AI, health tech, and energy, aiming to empower innovative companies that address significant global challenges. Notably, they have invested in Lunaphore, which has raised substantial funding across multiple rounds, indicating a commitment to advancing health tech solutions. Additionally, their investment in Genialis, which raised over $13 million to expand its ResponderID platform for cancer patients, highlights their engagement in the bioinformatics space. These transactions reflect Redalpine's strategic interest in supporting companies that are at the intersection of technology and health, particularly in the bioinformatics domain.


13. Kizoo Technology Capital

  • Website: kizoo.com
  • Type: Venture Capital
  • Headquarters: Karlsruhe, Baden-Württemberg, Germany
  • Founded year: 2000
  • Headcount: 1-10
  • Number of deals in 2024: 1
  • LinkedIn: kizoo

Kizoo Technology Capital GmbH is a biotechnology investment firm based in Karlsruhe, Baden-Württemberg, Germany, founded in 2000. The firm specializes in investing in innovative health solutions and rejuvenation biotech companies, providing both funding and expertise to startups in the biotechnology sector. Kizoo has been involved in several seed funding rounds for companies that are working on cutting-edge therapeutic solutions. Notable transactions include a $1.5 million investment in Antoxerene in 2017, a $1.35 million investment in Ichor Therapeutics in 2016, and a $1.5 million investment in MAIA Biotechnology in 2019. Additionally, Kizoo led an $8.4 million seed financing round for Revel Pharmaceuticals in 2022, a company focused on longevity therapeutics, which may involve bioinformatics in its research and development processes. These investments highlight Kizoo's commitment to supporting innovative biotech startups that could intersect with bioinformatics applications.


14. Bayern Kapital

  • Website: bayernkapital.de
  • Type: Venture Capital
  • Headquarters: Landshut, Bavaria, Germany
  • Founded year: 1995
  • Headcount: 11-50
  • Number of deals in 2024: 27
  • LinkedIn: bayern-kapital-gmbh

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria. They support their clients with financial resources and access to a network of industry experts, helping them navigate the challenges of growth and development in various sectors, including life sciences and software. Notably, Bayern Kapital has been involved in significant transactions within the life sciences domain, such as their investment in numares HEALTH, a provider of in-vitro diagnostic systems. This company has raised multiple rounds of funding with Bayern Kapital's backing, indicating the firm's commitment to supporting advancements in health diagnostics, which is closely related to bioinformatics.


15. Possible Ventures

  • Website: possible.ventures
  • Type: Venture Capital
  • Headquarters: Munich, Bavaria, Germany
  • Founded year: 2021
  • Headcount: 1-10
  • Number of deals in 2024: 9
  • LinkedIn: possible-vc

Possible Ventures is a venture capital firm based in Munich, Bavaria, Germany, founded in 2021. While their primary focus is on fintech, particularly through their investment in OwnHome, which offers a rent-to-own model for home ownership, they have also engaged in several transactions that align with the bioinformatics and biotech sectors. Notably, Possible Ventures participated in the funding round for Zafrens, a San Diego-based multi-modality drug discovery company that raised $23 million, indicating their interest in innovative healthcare solutions. Additionally, they were involved in the seed funding for Automata, a company focused on automation for scientists working in diagnostic, drug discovery, and biotech, further showcasing their engagement in the bioinformatics space. With a total of 9 investments in 2024, Possible Ventures is actively seeking opportunities across various sectors, including those relevant to bioinformatics.


16. Wellington Partners


Wellington Partners is a venture capital firm based in Munich, Bavaria, Germany, founded in 1998. The firm specializes in life sciences, investing in early- and growth-stage companies to provide capital and strategic support to entrepreneurs. Their investment strategy focuses on sectors such as therapeutics and medical devices, aiming to help innovative startups develop breakthrough technologies and achieve market success. Notably, Wellington Partners has been involved in significant transactions in the biotechnology space, including a $50 million Series A financing for SNIPR Biome, a CRISPR and microbiome biotech company, and a $12.5 million Seed funding round for Seamless Therapeutics, which is advancing its technology platform in the EU and US. These investments highlight their commitment to supporting companies that are at the forefront of technological advancements in life sciences, including areas relevant to bioinformatics.


17. Pureos Bioventures


Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies within the biotechnology sector. Founded with a focus on supporting biotechnology firms, Pureos Bioventures provides both capital and strategic guidance to help advance therapeutic solutions for severe diseases. In 2024, they participated in several significant funding rounds, including a $12.3 million Series B investment in Vico Therapeutics, which is developing therapies for spinocerebellar ataxia and Huntington's disease, utilizing antisense oligonucleotide technology—a key area where bioinformatics plays a crucial role. Additionally, they led a Series C financing round for Memo Therapeutics, which is working on therapies that also rely on advanced biotechnological methods. These transactions highlight Pureos Bioventures' commitment to supporting companies that leverage bioinformatics in their drug development processes.


18. Sartorius

  • Website: sartorius.com
  • Type: Corporate
  • Headquarters: Haßbergen, Lower Saxony, Germany
  • Founded year: 1870
  • Headcount: 10001+
  • Number of deals in 2024: 2
  • LinkedIn: sartorius

Sartorius AG, founded in 1870 and based in Haßbergen, Lower Saxony, Germany, is a leading biopharmaceutical supplier and laboratory equipment provider. The company focuses on offering innovative products and services for bioprocess solutions and laboratory applications, primarily serving customers in the biopharmaceutical and life sciences sectors. Sartorius has made several strategic acquisitions to enhance its capabilities in the bioinformatics domain. For instance, in 2017, Sartorius acquired Umetrics, a software company specializing in data analytics for biopharmaceutical development, which aligns closely with bioinformatics. Additionally, Sartorius has acquired Polyplus-transfection, a company that plays a role in the development of biotech drugs, further emphasizing its commitment to advancing biopharmaceutical technologies. These transactions highlight Sartorius's active engagement in the bioinformatics industry and its dedication to supporting the development of innovative solutions in this field.



Bioinformatics Insights: Key Investors in DACH


InvestorHeadquarterSizeFoundedDeals 2024
Novartis Venture FundBasel, Basel, Switzerland11-50199610
HBM Healthcare Investments AGZug, Zug, Switzerland1001-500020018
Nextech InvestZurich, Zurich, Switzerland11-50199813
NovartisBasel, Basel, Switzerland10001+19967
Leaps by BayerBerlin, Berlin, Germany11-50201516
Boehringer Ingelheim Venture FundIngelheim Am Rhein, Rhineland-Palatinate, Germany11-5020105
EvotecHamburg, Hamburg, Germany5001-1000019933
DebiopharmLausanne, Vaud, Switzerland201-50019794
RocheSwitzerland10001+18965
Verve VenturesZurich, Zurich, Switzerland11-50201025
BiomedVCBasel, Basel, Switzerland1-1020032
redalpineZurich, Zurich, Switzerland11-50200618
Kizoo Technology CapitalKarlsruhe, Baden-Württemberg, Germany1-1020001
Bayern KapitalLandshut, Bavaria, Germany11-50199527
Possible VenturesMunich, Bavaria, Germany1-1020219
Wellington PartnersMunich, Bavaria, Germany11-5019989
Pureos BioventuresArth, Schwyz, Switzerland11-507
SartoriusHaßbergen, Lower Saxony, Germany10001+18702


Want to find more investors focusing on the bioinformatics industry?

If you want to find more investors that are active in the bioinformaticsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!